Consequently, in a chemically-induced nonhuman primate model of liver fibrosis, treatment with a P2RX7 inhibitor improved histological characteristics of NASH, protecting from liver inflammation and fibrosis. Here, P2RX7 is linked to metabolic dysfunction-associated steatohepatitis.